The Global Corporate Venturing deal net rounds up investments from across the corporate innovation ecosystem.

The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.

The Global Corporate Venturing deal net rounds up the investments from across the corporate innovation ecosystem.

The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.

Web3 services provider Venly and genomic analysis technology provider Genome Insight each raised $23m while Rui Ye Lian helped Cedarlake Capital close a $189m fund.

The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.

Content personalisation technology provider Movable Ink and carbon-negative concrete developer Brimstone each raised $55m, with Intel and Amazon respectively among the investors.

Call centre software producer Replicant closed a $78m series B round backed by Salesforce Ventures while Ashvattha Therapeutics raised $69m from investors including strategic partner Huadong Medicine.

Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.